Insmed Incorporated
http://www.insmed.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Insmed Incorporated
EHA Preview: ASCO Overlap Gives Smaller Companies Chance To Shine
Cargo Therapeutics has got an early boost from its abstract to be presented the European meeting, while Shattuck has suffered on safety doubts for its CD47 inhibitor.
With A Transformational Year Underway, Insmed Ramps Up
With a reliable source of revenue in Arikayce and two key pulmonary late-stage trials reading out, Insmed aims to keep its commercial momentum going.
AN2 Looks To Shift Gears On Phase III Epetraborole Trial On Potentially Lackluster Results
The company said it was pausing enrollment in the Phase III segment of its Phase II/III trial because of efficacy in MAC lung disease.
Evaxion Cancer Vaccines Excite Investors
Shares in the Danish biotech have soared by 110% over plans to prioritize a novel category of AI-identified tumor antigens for its cancer vaccines.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
-
Drug Delivery
- Controlled Release
- Pulmonary
- Site Specific
-
Drug Delivery
-
Biotechnology
- Large Molecule
- Liposomes
- Other Names / Subsidiaries
-
- Insmed, Inc.
- Transave Inc.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice